ABSTRACT
Background & Aim: COVID-19 suggested to be treated with pleiotropic agents rather than single-target agents due to its complicated pathophysiology. There are currently no approved effective therapy that can stop the progression of COVID-19. Mesenchymal stem cells and its secretome have been studied in several in vivo lung disease models. The therapeutic application of Secretome therapy has been shown to be efficient in influenza infection, resulting in decreased alveolar fluid clearance and lung injury. This has been linked to attenuation of pro-inflammatory cytokine release, inflammatory cell recruitment, and increased alveolar macrophage content. In this article, we report case series of three COVID-19 patients received an experimental treatment with secretome from umbilical cord-derived mesenchymal stem cells (UC-MSCs) therapy in conjunction with recommended treatment protocols. Methods, Results & Conclusion: Three male patients who were tested positive for COVID-19 are initially presented with mild case of COVID-19 symptoms. The patients were treated with recommended treatment protocols of COVID-19 and add-on secretome from umbilical cord-derived mesenchymal stem cells (UC-MSCs) therapy. In this cases we report the administration of 1 cc and 0,5 cc secretome from UC-MSCs through nasal drop, with 0,5 cc and 0,25 cc for each nostril. Ground Glass Opacity (GGO) were checked by chest CT and the observation stop when patients were symptom-free and tested negative for (Figure Presented)Figs 1 and 2 COVID-19. Significant improvement showed in patients’s respiratory symptoms include GGO profiles, proven by chest CT and no side effects reported. Our report showed that nasal drop of secretome from UC-MSC therapy in patients with mild COVID-19 is safe and well tolerated. No serious therapy-associated adverse event was observed. Further study with more patients and comprehensive biomarker testing is needed to evaluate the efficacy of secretome from UC-MSC therapy to improve long-term treatment outcomes in COVID-19 patients